CStone Pharmaceuticals (HKSE:02616) Growth Rank : 0 (As of May. 25, 2024)

View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals Growth Rank?

CStone Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

CStone Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

CStone Pharmaceuticals (HKSE:02616) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (HKSE:02616) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

CSPHF:USA PH4:Germany

Address

218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123

Website

https://www.cstonepharma.com

CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

Executives

Su Zhou Gong Ye Yuan Qu Zheng Ze Yuan Shi Chuang Ye Tou Zi Qi Ye You Xian He Huo	2101 Beneficial owner
Su Zhou Gong Ye Yuan Qu Zheng Ze Ji Ming Gu Quan Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Zheng Ze Jian Kang Chuang Ye Tou Zi Guan Li Zhong Xin You Xian He Huo	2501 Other
Su Zhou Gong Ye Yuan Qu Yuan He Yuan Dian Chuang Ye Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Guan Wei Hui	2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Jing Ji Fa Zhan You Xian Gong Si	2201 Interest of corporation controlled by you
Su Zhou Yuan He Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Fei Jianjiang	2201 Interest of corporation controlled by you
Wuxi Healthcare Ventures Ii, L.p.	2101 Beneficial owner
Wuxi Healthcare Management, Llc	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
Gic Private Limited	2102 Investment manager
Jiang Frank Ningjun	2307 Founder of a discretionary trust who can infl
Graceful Beauty Limited	2101 Beneficial owner
Boyu Capital Holdings Ltd.	2201 Interest of corporation controlled by you

CStone Pharmaceuticals (HKSE:02616) Headlines

No Headlines